	US 12,448,417 B2
	Cryptosporidiosis vaccine
Markus Hendrikus Van Roosmalen, Berkel-Enschot (NL); and Koen Gevers, Boxmeer (NL)
Assigned to Intervet Inc., Rahway, NJ (US)
Appl. No. 17/784,690
Filed by Intervet Inc., Madison, NJ (US)
PCT Filed Dec. 17, 2020, PCT No. PCT/EP2020/086646 § 371(c)(1), (2) Date Jun. 13, 2022, PCT Pub. No. WO2021/122896, PCT Pub. Date Jun. 24, 2021.
Claims priority of application No. 19217573 (EP), filed on Dec. 18, 2019; and application No. 20172007 (EP), filed on Apr. 29, 2020.
Prior Publication US 2023/0015910 A1, Jan. 19, 2023
Int. Cl. C07K 14/44 (2006.01); A61K 35/20 (2006.01); A61K 39/00 (2006.01); A61K 39/002 (2006.01); A61K 39/39 (2006.01); A61P 1/12 (2006.01); A61P 33/02 (2006.01); C07K 16/20 (2006.01); C12P 21/02 (2006.01)

CPC C07K 14/44 (2013.01) [A61K 35/20 (2013.01); A61K 39/002 (2013.01); A61K 39/39 (2013.01); A61P 1/12 (2018.01); A61P 33/02 (2018.01); C07K 16/20 (2013.01); C12P 21/02 (2013.01); A61K 2039/552 (2013.01); A61K 2039/55511 (2013.01)]

8 Claims

1. A Cryptosporidium gp40 protein, wherein that the gp40 protein comprise one or more amino acids alkylated by an aziridine.